Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic cuts costs

This article was originally published in The Gray Sheet

Executive Summary

Planned elimination of 900 positions is part of an ongoing restructuring effort aimed at saving $125 million annually and is expected to be complete by next April, the firm discloses in a Sept. 5 10-Q filing with the Securities and Exchange Commission. The reductions in force, of which about 350 had been achieved as of July 27, will include early retirements, and voluntary and involuntary separations. The effort, which began earlier this year, includes driving manufacturing efficiencies in the firm's cardiovascular business, downsizing its Physio-Control external defibrillator unit and rebalancing resources in its cardiac rhythm disease management business "in response to current market dynamics," the firm explains (1"The Gray Sheet" Aug. 27, 2007, p. 4)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel